Table 1 Clinical characteristics of study subjects

M/F (n)

82/60

19/18

18/17

23/13

22/12

Age (years)

62.2 ± 10.6

55.6 ± 9.6

59.3 ± 11.8

65.5 ± 8.6†

68.9 ± 6.5†

Duration of type 2 diabetes (years)

12.6 ± 9.4

10.1 ± 8.7

11.3 ± 8.4

13.7 ± 9.7

15.5 ± 10.2

Hospital stay (days)

12.2 ± 2.8

13.0 ± 3.5

11.7 ± 2.4*

12.4 ± 2.9

11.8 ± 2.2†

Diet calorie (kcal)

1546 ± 183

1576 ± 205

1529 ± 171

1544 ± 176

1532 ± 181

BMI on admission (kg/m²)

26.3 ± 5.9

27.2 ± 5.6

26.8 ± 6.2

25.2 ± 6.7

26.1 ± 4.8

Body weight on admission (kg)

68.6 ± 17.0

72.5 ± 18.0

70.0 ± 18.0

64.5 ± 16.4

67.1 ± 15.0

HbA1c on admission (%)

9.8 ± 2.1

10.6 ± 2.4

9.4 ± 1.8*

9.8 ± 2.0*

9.4 ± 2.0

GA on admission (%)

25.4 ± 7.9

26.0 ± 7.7

23.2 ± 7.5

27.8 ± 9.3

24.4 ± 6.5

BMI at discharge (kg/m²)

25.3 ± 5.5

26.3 ± 5.3

26.0 ± 6.0

23.9 ± 6.1

25.2 ± 4.6

Body weight at discharge (kg)

66.0 ± 16.2

70.2 ± 17.2

67.9 ± 17.4

61.1 ± 16.6

64.7 ± 14.3

GA at discharge (%)

21.9 ± 5.6

22.1 ± 5.0

19.9 ± 5.4

24.2 ± 6.9

21.3 ± 4.5

EPA (μg/mL)

60.1 ± 32.0

31.8 ± 11.0

47.9 ± 13.6†

63.9 ± 17.5†

99.2 ± 32.8†

AA (μg/mL)

208.5 ± 54.8

232.0 ± 58.0

223.3 ± 63.1

198.0 ± 43.9*

178.7 ± 33.7†

EPA/AA

0.31 ± 0.19

0.14 ± 0.03

0.22 ± 0.02†

0.32 ± 0.05†

0.57 ± 0.19†

Retinopathy (N/S/P)

96/29/17

22/10/5

24/4/7

26/8/2

24/7/3

Neuropathy (n)

54

10

10

19

15

Nephropathy (Stage 1/2/3/4)

91/36/13/2

22/13/1/1

20/7/8/0

26/9/1/0

23/7/3/1

 Insulin/SU/Glinides/TZD

44/39/10/31

11/11/1/7

10/5/5/6

13/8/2/6

10/15/2/12

 BG/α-GI/DPP-4I

66/26/73

25/6/16

13/7/20

10/6/17

18/7/20

 SGLT2I/GLP1RA

19/13

8/7

6/1

2/3

3/2

 Treatment for dyslipidemia (n)

118

23

35

26

34

 Treatment for hypertension (n)

69

19

12

15

23